USA Assembled

USA Assembled

Tolmar is the original innovator and manufacturer of ELIGARD. All ELIGARD assembly takes place at our state-of-the-art R&D and assembling facilities that occupy more than 340,000 square feet in Northern Colorado.

Tolmar’s commercial organization is located in Buffalo Grove, Illinois, with a sales force deployed across the United States. Explore our company locations:

Headquarters, Commercial Operations:

Tolmar Pharmaceuticals, Inc.
485 W. Half Day Road, Suite 400
Buffalo Grove, IL 60089
224-880-5770

Headquarters, Assembly & R&D:

Tolmar, Inc.
701 Centre Ave
Fort Collins, CO 80526
970-212-4500
1-877-9TOLMAR (1-877-986-5627)

Additional assembly locations:

1201 Cornerstone Drive
Windsor, CO 80550

Tolmar supports the supporters

Rallying behind those who help the prostate cancer community reflects both our mission and our values. Tolmar strives to be an advocate for patients through our therapies and through our community engagement.

We support national and local professional associations and patient advocacy groups:

  • American Urological Association (AUA)
  • Large Urology Group Practice Association (LUGPA)
  • American Society of Clinical Oncology (ASCO)
  • Society of Urologic Oncology (SUO)
  • Society of Urologic Nurses and Associates (SUNA)
  • ZERO – The End of Prostate Cancer

IMPORTANT SAFETY INFORMATION

Expand Minimize

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. See package insert for full Prescribing and Safety Information.